tbuckley/cabot-search huggingface dataset:
Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect® MM Registry
Authors: Lynne I. Wagner, Kathleen Toomey, Sikander Ailawadhi, Sundar Jagannath, Cristina Gasparetto, Brian G.M. Durie, Mohit Narang, Robert M. Rifkin, Howard R. Terebelo, James L. Omel, James W. Hardin, Hans C. Lee, Shankar Srinivasan, Liang Liu, Mazaher Dhalla, Donna Catamero, Rafat Abonour
Journal: Blood (2019)
Anti-Tumor Effect of the EZH1/2 Dual Inhibitor Valemetostat Against Diffuse Large B-Cell Lymphoma Via Modulation of B-Cell Receptor Signaling and c-Myc Signaling Pathways
Authors: Yasuhiro Hama, Toshihiro Banjo, Daisuke Honma, Yoshimi Takata, Emi Nosaka, Machiko Shiroishi, Kenji Watanabe, Yuka Yamamoto, Tsuyoshi Hirata, Rika Nakano, Koichiro Inaki, Hiroki Goto, Yusuke Totoki, Miki Kataoka, Kyungtaek Lim, Chisa Wada, Eiji Kumazawa, Shinji Tsutsumi
Journal: Blood (2019)
DDIS-17. DEVELOPMENT OF BRAIN-PENETRANT EGFR INHIBITORS FOR CNS MALIGNANCIES
Authors: Jonathan Tsang, Lorenz Urner, Christopher Tse, Lynn Baufeld, Kym Faull, Peter Clark, Timothy Cloughesy, Michael Jung, David Nathanson
Journal: Neuro-Oncology (2019)

Abstract The epidermal growth factor receptor (EGFR) is altered in nearly 60% of glioblastoma (GBM) tumors, however, EGFR tyrosine kinase inhibitors (TKIs) have failed to improve outcomes for patients with GBM. This can be attributed to the inability of clinically available EGFR TKIs (e.g., erlotinib, gefitinib, lapatinib, afatinib, cetuximab) to effectively cross the blood-brain-barrier (BBB) and reach adequate pharmacological levels for a tumor response. Herein, we performed a structure-activity relationship (SAR) to obtain EGFR TKIs with both high brain penetrance and potency against EGFR-activated GBM cells. From over 80 novel compounds synthesized, our lead EGFR TKI—JCN068—exhibited exceptional BBB penetration (350% brain to plasma) while also having optimal ADME properties (60% oral bioavailability, ~5 hr half-life, &gt;100 µg/mL solubility, etc). Moreover, JCN068 demonstrated picomolar potency against purified EGFR kinase, 1000-fold selectivity for EGFR relative to other kinases, and nanomolar activity against EGFR-altered, GBM patient-derived cells in culture. Importantly, JCN068 demonstrated superior efficacy—with negligible toxicity—compared to clinically available small molecule EGFR TKIs (erlotinib and lapatinib) against multiple EGFR-altered patient-derived orthotopic GBM xenografts. Due to these excellent drug-like properties, JCN068 is currently progressing towards clinical development for EGFR-activated GBM patients.
EXTH-18. PEPTIDE NANO-STRUCTURES ENHANCE PEDIATRIC BRAIN TUMOR CHEMOTHERAPEUTIC EFFICACY
Authors: Guifa XI, Ashorne Mahenthiran, Benjamin Best, Sonali Nayak, Cara Smith, Mark McClendon, Barbara Mania-Farnell, John Kessler, Charles James, Samuel Stupp, Tadanori Tomita
Journal: Neuro-Oncology (2019)

Abstract Pediatric gliomas, particularly high-grade gliomas, which include diffuse intrinsic pontine gliomas (DIPGs), are among the most formidable and devastating cancers in children. These tumors remain incurable, despite many treatment approaches. We recently identified a small population of glioma cells with stem-like features in pediatric gliomas (glioma stem cells: GSCs), that may be responsible, for therapeutic resistance. Bone morphogenetic protein 4 (BMP4), essential for CNS development, increases GSC therapeutic sensitivity and is a promising adjuvant for glioma treatment. Mechanisms through which BMP4 increases therapeutic sensitivity need to be elucidated, as this can lead to identification of additional treatment targets and delivery systems for BMP4 administration in a clinical setting. Additionally, extension of BMP4 short half-life would enhance its’ clinical application. Here we show that BMP4 increases chemosensitivity by decreasing H3K4me3 at the promoter of multidrug resistant gene 1 (MDR1), resulting in decreased MDR1 expression. BMP4 appears to bring about this effect by decreasing hSETD1A, an H3K4me3 methyltransferase. Our work also demonstrates the first use of a novel sulfated glycopeptide (glyco-PA) nanostructure as a vector for BMP4 delivery. Glyco-PA markedly extended and enhanced BMP4 function, and increased chemotherapeutic anti-tumor activity against pediatric malignant glioma cells in culture. Overall, this work illuminates BMP4 effects on pediatric glioma therapeutic sensitivity through epigenetic mechanisms, and demonstrates the potential of bioactive glyco-PA nanostructures as a delivery mechanism for treating pediatric malignant gliomas and other tumors.
Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast tumor
Authors: Chuanzhong Ye, Qiuyin Cai, Wanqing Wen, Larry Pierce, Regina Courtney, Yu-Tang Gao, Xiao Ou Shu, Wei Zheng
Journal: Cancer Research (2007)

1727  The mitochondrial DNA (mtDNA) 4977-bp deletion (ΔmtDNA4977), one of the most frequently observed mtDNA mutations in human tissues, has been suggested to play a role in carcinogenesis. Only a limited number of studies with small sample sizes have been conducted to evaluate ΔmtDNA4977 in tissue samples from patients with breast cancer or benign breast disease, and the findings have been inconsistent. The inconsistency in previous studies may be in part due to the use of non-quantitative detecting methods or primers which co-amplify nuclear DNA. In this study, we developed a quantitative real-time PCR assay to assess the level of the ΔmtDNA4977 in tissue samples of malignant and benign breast tumors. The PCR primers were designed to target mtDNA with non-homologue to nuclear DNA sequences to amplify PCR products containing the ΔmtDNA4977 and the total mtDNA (mtDNAtotal). The PCR products were cloned to plasmids and used for constructing standard curves in the copy number quantifications. TaqMan real-time PCR was performed and the copy number of ΔmtDNA4977 and mtDNAtotal were calculated from corresponding standard curves. We investigated ΔmtDNA4977 in tumor tissue and adjacent normal tissue from 55 primary breast cancer patients and 21 patients diagnosed with benign breast diseases (BBD) collected in the Shanghai Breast Cancer Study. The ΔmtDNA4977 was detected in all of the samples with the levels varying from 0.000149% to 7.0%. The ΔmtDNA4977 levels were lower in tumor tissues than in adjacent normal tissues in both breast cancer and BBD subjects. The differences, however, were not statistically significant. No significant difference was found in the ΔmtDNA4977 levels between breast cancer and BBD in both tumor tissues and adjacent normal tissues. The ΔmtDNA4977 levels were not significantly associated with clinicopathological characteristics (age, histology, tumor stage, and ER/PR status) in breast cancer or BBD patients. These results do not support the notion that the mitochondrial DNA 4977-bp deletion plays a major role in breast carcinogenesis.
Lactate Dehydrogenase Is a Key Prognostic Factor in Acute Myeloid Leukemia and Lymphoma Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Mika Geva, Roni Shouval, Joshua A Fein, Ivetta Danylesko, Noga Shem-Tov, Ronit Yerushalmi, Avichai Shimoni, Arnon Nagler
Journal: Blood (2019)
B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions
Authors: Safaa M. Ramadan, Alessandro Cignetti, Simona Sammassimo, Enrico Derenzini, Giusy Ceparano, Tommaso Radice, Federica Gigli, Stefano Fiori, Valentina Tabanelli, Martina Milani, Emanuela Omodeo Sale', Sara Gandini, Daniela Gottardi, Giuseppe Saglio, Stefano Pileri, Corrado Tarella
Journal: Blood (2019)
Thyrotoxicosis in Childhood
Authors: K. M. Saxena
Journal: BMJ (1965)

Professor Harrison suggests that cilia remaining at the posterior part of the nose are unable to transport the relatively large particles of snuff back to the nasopharynx, and this, he thinks, accounts for the incidence of nasopharyngeal carcinoma being much the same in the Bantu as in the European.In fact, flecks of snuff can be seen at the back of the throat even after many years of snufftaking.I remember the well-controlled start of surprise when my family doctor looked at my throat and saw what he thought at first glance were petechial haemorrhages.-Iam, etc.,
Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience
Authors: Logan Moore, Trace Bartels, Daniel O. Persky, Abhijeet Kumar, Ivo Abraham, Lauren Sanders, Alicia Ortega, Alyssa Henglefelt, Ali McBride
Journal: Blood (2019)
SSBP1 faux pas in mitonuclear tango causes optic neuropathy
Authors: Lina Zelinger, Anand Swaroop
Journal: Journal of Clinical Investigation (2019)

Mitochondrial dysfunction or loss is evident in neurodegenerative diseases. Furthermore, mitochondrial DNA (mtDNA) mutations associated with NADH dehydrogenase subunits and nuclear gene mutations that affect mitochondrial function result in optic neuropathies. In this issue of the JCI, Del Dotto et al. and Piro-Mégy et al. identify heterozygous mutations in nuclear-encoded mitochondrial single-strand binding protein 1 (SSBP1) in patients with apparently dominant optic neuropathy with or without extraocular phenotypes. Both research groups reported similar mitochondrial findings in response to SSBP1 mutations. However, the specific SSBP1 mitochondria–associated function in retinal ganglion cells (RGCs) and the resulting optic nerve remains unclear. We suggest that high expression of SSBP1 during RGC differentiation is critical for mtDNA maintenance to produce appropriate optic nerve connectivity and that SSBP1 mutations in dominant optic atrophy patients do not permit stable binding to N6-methyldeoxyadenosine on the heavy strand involved with replication, leading to disruptions of mtDNA and, eventually, optic nerve dysfunction.
Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Authors: Chunrui Li, Jue Wang, Di Wang, Guang Hu, Yongkun Yang, Xiaoxi Zhou, Li Meng, Zhenya Hong, Liting Chen, Xia Mao, Min Xiao, Jianfeng Zhou
Journal: Blood (2019)
Comparative genetic architectures of schizophrenia in East Asian and European populations
Authors: Max Lam, Chia-Yen Chen, Zhiqiang Li, Alicia R. Martin, Julien Bryois, Xixian Ma, Helena Gaspar, Masashi Ikeda, Beben Benyamin, Brielin C. Brown, Ruize Liu, Wei Zhou, Lili Guan, Yoichiro Kamatani, Sung-Wan Kim, Michiaki Kubo, Agung A. A. A. Kusumawardhani, Chih-Min Liu, Hong Ma, Sathish Periyasamy, Atsushi Takahashi, Zhida Xu, Hao Yu, Feng Zhu, Wei J. Chen, Stephen Faraone, Stephen J. Glatt, Lin He, Steven E. Hyman, Hai-Gwo Hwu, Steven A. McCarroll, Benjamin M. Neale, Pamela Sklar, Dieter B. Wildenauer, Xin Yu, Dai Zhang, Bryan J. Mowry, Jimmy Lee, Peter Holmans, Shuhua Xu, Patrick F. Sullivan, Stephan Ripke, Michael C. O’Donovan, Mark J. Daly, Shengying Qin, Pak Sham, Nakao Iwata, Kyung S. Hong, Sibylle G. Schwab, Weihua Yue, Ming Tsuang, Jianjun Liu, Xiancang Ma, René S. Kahn, Yongyong Shi, Hailiang Huang
Journal: Nature Genetics (2019)
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas
Authors: Natasha Rekhtman, Joseph Montecalvo, Jason C. Chang, Deepu Alex, Ryan N. Ptashkin, Ni Ai, Jennifer L. Sauter, Brie Kezlarian, Achim Jungbluth, Patrice Desmeules, Amanda Beras, Justin A. Bishop, Andrew J. Plodkowski, Mrinal M. Gounder, Adam J. Schoenfeld, Azadeh Namakydoust, Bob T. Li, Charles M. Rudin, Gregory J. Riely, David R. Jones, Marc Ladanyi, William D. Travis
Journal: Journal of Thoracic Oncology (2019)

Highly aggressive thoracic neoplasms characterized by SMARCA4 (BRG1) deficiency and undifferentiated round cell or rhabdoid morphology have been recently described and proposed to represent thoracic sarcomas. However, it remains unclear whether such tumors may instead represent sarcomatoid carcinomas, and how their clinicopathologic characteristics compare with those of nonsarcomatoid SMARCA4-deficient non-small cell lung carcinomas (SD-NSCC).We identified 22 SMARCA4-deficient thoracic sarcomatoid tumors (SD-TSTs) with round cell and/or rhabdoid morphology and 45 SD-NSCCs, and comprehensively analyzed their clinicopathologic, immunohistochemical, and genomic characteristics using 341-468 gene next-generation sequencing and other molecular platforms.The relationship of SD-TSTs with NSCC was supported by (1) the presence of NSCC components juxtaposed with sarcomatoid areas in five cases, (2) focal expression of NSCC lineage markers TTF1 or p40 in four additional cases, (3) smoking history in all except one patient (mean = 51 pack-years), accompanied by genomic smoking signature, and (4) high tumor mutation burden (mean = 14.2 mutations per megabase) and mutations characteristic of NSCC in a subset. Compared with SD-NSCCs, SD-TSTs exhibited considerably larger primary tumor size (p < 0.0001), worse survival (p = 0.004), and more frequent presentation at younger age (30-50 years) despite heavier smoking history. Distinctive pathologic features of SD-TSTs included consistent lack of adhesion molecule claudin-4, SMARCA2 (BRM) codeficiency, and frequent expression of stem cell markers.SD-TSTs represent primarily smoking-associated undifferentiated/de-differentiated carcinomas rather than primary thoracic sarcomas. Despite their histogenetic relationship with NSCC, these tumors have unique clinicopathologic characteristics, supporting their recognition as a distinct entity. Further studies are warranted to determine therapeutic approaches to this novel class of exceptionally aggressive thoracic tumors.
Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Lam T. Khuat, Catherine T. Le, Chien-Chun Pai, Robin Shields-Cutler, Shernan Holtan, Armin Rashidi, Sarah Parker, Dan Knights, Jesus I. Luna, Cordelia Dunai, Ziming Wang, Ian R. Sturgill, Kevin Stoffel, Alexander A. Merleev, Emanual Maverakis, Helen Raybould, Mingyi Chen, Robert J. Canter, Arta M. Monjazeb, James L. M. Ferrara, John E. Levine, Dan L. Longo, Mehrdad Abedi, Bruce R. Blazar, William J. Murphy
Journal: Blood (2019)
Echocardiographic Probability of Pulmonary Hypertension in Myeloproliferative Neoplasms Patients in Chiang-Mai University
Authors: Yanika Jindamai, Ekarat Rattarittamrong, Arintaya Phrommintikul, Lalita Yongsmith, Thanawat Rattanathammethee, Chatree Chai-Adisaksopha, Adisak Tantiworawit, Lalita Norasetthada
Journal: Blood (2019)
Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions
Authors: Vip Viprakasit, Ali Taher, Olivier Hermine, John Porter, Antonio Piga, Kevin H. M. Kuo, Thomas Coates, Ersi Voskaridou, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Abderrahmane Laadem, Jeevan K. Shetty, Wen-Ling Kuo, Dimana Miteva, Tatiana Zinger, Daniel Sinsimer, Peter G. Linde, Maria Domenica Cappellini
Journal: Blood (2019)
EPID-06. IMMUNE-RELATED PLASMA BIOMARKERS IN GLIOBLASTOMA
Authors: Camilla Bjørnbak Holst, Ib Jarle Christensen, Jane Skjoeth-Rasmussen, Hans Skovgaard Poulsen, Petra Hamerlik, Julia Sidenius Johansen
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Glioblastoma (GBM) is an aggressive and malignant primary brain tumor with limited treatment options and a dismal prognosis. Immunotherapy is advancing in other types of cancer but has not yet proven effective in glioblastoma. Prognostic and predictive biomarkers and new treatment targets are urgently needed. MATERIAL AND METHODS 158 patients with glioma WHO grade II-IV were included in the study. Plasma was analyzed for interleukin (IL)-6, YKL-40 (Gene: CHI3L1) and 91 other immune-related protein biomarkers by ELISA or/and Olink technology. CHI3L1 rs4950928 genotyping was analyzed on DNA extracted from whole-blood. RESULTS Fourteen of 92 immune-related biomarkers in plasma detected with the Olink immuno-oncology array were related with tumor grade or/and type (p&lt; 0.05) (corrected for age), whereas plasma IL-6 and YKL-40 did not change with tumor grade. In univariate analysis of plasma from 94 patients with newly diagnosed GBM higher baseline IL-6 was associated with short OS (HR=1.19 (per 2-fold change in IL-6), p=0.04), YKL-40 showed a similar trend (HR=1.20 (per 2-fold change in YKL-40), p=0.056) and high/low baseline levels of additional 15 immune-related biomarkers (e.g. CD244, Granzyme B, ICOS ligand, IL-8 and Pleiotrophin) were associated with short OS (p&lt; 0.05). Genetic variation in YKL-40 was associated with plasma YKL-40 levels (+/+ vs. -/+ vs. -/-, p=0.0004) but not with OS in patients with GBM (HR= 0.78 (+/+ vs. -/+), p=0.32). CONCLUSION High levels of several immune-related biomarkers in plasma including IL-6, IL-8, CD244, Granzyme B, ICOS ligand, and Pleiotrophin from patients with glioblastoma were related or inversely related to OS.
Assessing Venous Thromboembolism Risk in Critically Ill Children: A Report from the Children's Hospital-Acquired Thrombosis (CHAT) Consortium
Authors: Julie Jaffray, Arash Mahajerin, Brian R. Branchford, Anh Thy Nguyen, Ernest Amankwah, Michael Silvey, Stacy E. Croteau, James D. Cooper, John H. Fargo, Nihal Bakeer, Amy Stillings, Emily Krava, E Vince S Faustino, Neil A. Zakai, Guy Young, Neil A Goldenberg
Journal: Blood (2019)
Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment
Authors: Tereza Popkova, Katarina Hradska, Jana Mihalyova, Michaela Skorupova, Tomas Jelinek, Juraj Duras, Zdenek Koristek, Milan Navratil, Katerina Benkova, Hana Plonkova, Jana Zuchnicka, Jaromir Gumulec, Roman Hajek
Journal: Blood (2019)
Neostigmine-resistant Curarization
Authors: R. J. H. Hodges
Journal: BMJ (1956)

The reported anti-allergic and epinephrine-producing effects of a tyrosineniacinamide-pyridoxine mixture (Tyral) were investigated. Rats fed diets containing 4 per cent of this mixture showed no increase in blood pressure, adrenal weight or epinephrine content of the adrenals after periods of feeding of 3 to 12 weeks. Guinea pigs fed diets containing 4 per cent of the mixture showed no evidence of protection from mild anaphylactic shock. The claims made for this mixture as an effective epinephrine precursor and as an anti-allergic agent were not confirmed in experimental animals.
Identification of Tablets
Authors: S W SIMMONS, W A RASMUSSEN
Journal: BMJ (1965)

court does not have the advantage of seeing the witnesses, so that it will be reluctant to disturb a finding of an inferior tribunal that one witness is more credible than another.But the appeal court will be willing to say in appropriate cases that there was no evidence to support a particular finding of fact, or that the primary facts found do not support the inferences of fact drawn from them.When appealing from a reasoned judgment of, say, a High Court judge, the above principles have a logical and clear foundation.But the G.M.C. gives no reasons for its
Mevalonate metabolism–dependent protein geranylgeranylation regulates thymocyte egress
Authors: Xingrong Du, Hu Zeng, Shaofeng Liu, Cliff Guy, Yogesh Dhungana, Geoffrey Neale, Martin O. Bergo, Hongbo Chi
Journal: The Journal of Experimental Medicine (2019)

Thymocyte egress is a critical determinant of T cell homeostasis and adaptive immunity. Despite the roles of G protein–coupled receptors in thymocyte emigration, the downstream signaling mechanism remains poorly defined. Here, we report the discrete roles for the two branches of mevalonate metabolism–fueled protein prenylation pathway in thymocyte egress and immune homeostasis. The protein geranylgeranyltransferase Pggt1b is up-regulated in single-positive thymocytes, and loss of Pggt1b leads to marked defects in thymocyte egress and T cell lymphopenia in peripheral lymphoid organs in vivo. Mechanistically, Pggt1b bridges sphingosine-1-phosphate and chemokine-induced migratory signals with the activation of Cdc42 and Pak signaling and mevalonate-dependent thymocyte trafficking. In contrast, the farnesyltransferase Fntb, which mediates a biochemically similar process of protein farnesylation, is dispensable for thymocyte egress but contributes to peripheral T cell homeostasis. Collectively, our studies establish context-dependent effects of protein prenylation and unique roles of geranylgeranylation in thymic egress and highlight that the interplay between cellular metabolism and posttranslational modification underlies immune homeostasis.
Trichomonas Vaginalis Infection in the Male
Authors: W. E. Coutts, R. Vargas-Salazar, E. Silva-Inzunza, R. Olmedo, R. Turteltaub, J. Saavedra
Journal: BMJ (1955)

CHRONIC LEAD-POISONING BRDICTISH 885 of lead-poisoning and promoted the excretion of large amounts of lead in the urine.No toxic effects were observed.The administration of para-thor-mone during treat- ment with versenate did not increase the rate of excre- tion of lead in the urine above that obtained by versenate alone.The chemistry, pharmacology, and method of use of versenate are discussed.
DDIS-25. PENTAMIDINE; A NEW CHEMOTHERAPY TARGETING ON GLIOMA STEM LIKE CELLS
Authors: Sho Tamai, Shabierjiang Jiapaer, Guangtao Zhang, Jiakang Zhang, Yi Wang, Hemragul Sabit, Shingo Tanaka, Masashi Kinoshita, Atsushi Hirao, Mitsutoshi Nakada
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Glioblastoma (GBM) is the most common primary malignant brain tumors. Despite aggressive therapies, median overall survival of patients who suffered from GBM is only 18 months. Furthermore, there is no effective therapy for glioma stem cells (GSCs), which act as forming tumors. Herein, we newly identified pentamidine, an antiprotozoal drug, is effective for GSCs by using drug repositioning approach. METHOD We used patient-derived glioma stem like cell lines KGS01, KGS07 which were established at Kanazawa University. We investigated proliferation ability, stemness and intracellular signal change by proliferation assay, sphere forming assay and western blotting, respectively. RESULT: Proliferation ability was prohibited by pentamidine in both cell lines. The half maximal inhibitory concentration was 1 - 5 μM. Sphere forming assay revealed that size and number of spheres were reduced in both cell lines, depending on concentration of pentamidine. Phosphorylation of extracellular signal-related kinase (ERK) and signal transducer and activator of transcription 3 (STAT3) were suppressed by pentamidine. DISCUSSION Pentamidine is known as the therapeutic drug for pneumocystis jirovecii. In this study, pentamidine suppressed proliferation activity and stemness in both glioma stem cell lines. Previous papers revealed pentamidine had anti-tumor effects for some types of tumor cell lines, however, therapeutic effect for tumor stem cells have never been mentioned. CONCLUSION These results suggest that pentamidine would be therapeutic drug for GSCs by suppressing phosphorylation of ERK and STAT3.
Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)
Authors: Ing S Tiong, Richard Dillon, Adam Ivey, Tse-Chieh Teh, Catherine Vassili, Vanessa Roma Donati, David Taussig, Nicola Potter, Jelena Jovanovic, Anju Kanda, Manohursingh Runglall, Nicola Foot, Mikel Valganon, Nigel H. Russell, Kavita Raj, Anthony P Schwarer, Chun Yew Fong, Andrew Grigg, Steven Knapper, Andrew H. Wei
Journal: Blood (2019)
A Comprehensive Study of Human Integrins in Pediatric Lymphoblastic Leukemia Supports a Role of CD49f (Integrin α6) in the Localization to Bone Marrow but Not Spinal Fluid
Authors: Bibi F. S. S. Scharff, Signe Modvig, Maria Thastrup, Mette Levinsen, Matilda Degn, Lars Peter Ryder, Kjeld Schmiegelow, Claus René Lykke Christensen, Hanne Vibeke Marquart
Journal: Blood (2019)